journal
MENU ▼
Read by QxMD icon Read
search

Memo

journal
https://www.readbyqxmd.com/read/29606982/esmo-2017-my-personal-highlights
#1
Barbara Kiesewetter, Mircea Dediu, Rupert Bartsch
This article is not intended to be a comprehensive review of all highlights presented at the recent ESMO Annual Meeting, but rather a summary from a personal point of view in three very different fields of oncology. Breast cancer and lung cancer are traditionally in the focus of interest, and again, relevant new data were presented. The third part of this overview is focused on novel treatment strategies in malignant lymphoma, a field that is also quickly evolving and traditionally underrepresented at meetings dealing with solid cancers...
2018: Memo
https://www.readbyqxmd.com/read/29606981/pleural-effusion-in-11-14-translocation-q1-multiple-myeloma-in-the-setting-of-proteasome-inhibitor-presents-therapeutic-complexity
#2
Malik Ghannam, Maria Bryan, Erik Kuross, Brent Berry
Background: Primary malignant pleural effusion has been reported in about 134 cases of multiple myeloma (MM). Associated pleural effusions in cases of MM portend a poor prognosis and identifying them is highly relevant. Reported is the case of a man diagnosed with MM who developed primary myelomatous pleural effusion in the setting of multiple relapses and subsequent mortality within 2 months of the pleural effusion diagnosis. Presentation: A 61-year-old African American man was diagnosed with MM in 2011...
2018: Memo
https://www.readbyqxmd.com/read/29606980/short-overview-on-the-current-standard-of-treatment-in-newly-diagnosed-multiple-myeloma
#3
REVIEW
Ella Willenbacher, Agnes Balog, Wolfgang Willenbacher
The treatment of newly diagnosed multiple myeloma has changed dramatically over the past 20 years, from near uniform application of chemotherapy to a patient performance status- and risk-based approach. Furthermore, initiation of treatment criteria have evolved from a pure end-organ damage-based definition to include risk factors of transformation to frank myeloma. Besides, the mainly cytogenetically defined Multiple Myeloma (MM) risk status, transplant eligibility of patients still serves primarily to allocate patients within a rational treatment algorithm...
2018: Memo
https://www.readbyqxmd.com/read/29606979/pd-1-and-pd-l1-inhibitors-after-platinum-based-chemotherapy-or-in-first-line-therapy-in-cisplatin-ineligible-patients-dramatic-improvement-of-prognosis-and-overall-survival-after-decades-of-hopelessness-in-patients-with-metastatic-urothelial-cancer
#4
REVIEW
Irene Resch, Shahrokh F Shariat, Kilian M Gust
Until recently, there were no true innovations in the management of locally advanced (aUC) and metastatic urothelial cancer (mUC) in the last three decades. Vinflunine has been approved by the EMA (European Medicines Agency) with only limited improvement compared to best supportive care in second line treatment. In addition, gemcitabine/cisplatin has been established as an alternative to methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC). The advent of checkpoint inhibitors (CPI) revolutionized the care of these patients, transforming a unanimously deadly disease into one with hope through sustained disease control...
2018: Memo
https://www.readbyqxmd.com/read/29606978/my-burning-issues-in-the-neoadjuvant-treatment-for-breast-cancer
#5
REVIEW
Elisabeth S Bergen, Rupert Bartsch
A combination of anthracyclines and taxanes remains the standard of care for neoadjuvant chemotherapy (NACT) resulting in increased breast conservation rate (BCR) and decreased recurrence rate [1]. Whether pathological complete response (pCR) could be an appropriate surrogate parameter for long-term survival is still a matter of debate. In patients with triple-negative breast cancer (TNBC) and HER2-positive breast cancer (BC), a six to nine times higher risk for relapse has been reported if no pCR was achieved [2, 3]...
2018: Memo
https://www.readbyqxmd.com/read/29606977/anti-angiogenic-therapies-in-brain-metastases
#6
REVIEW
Anna S Berghoff, Matthias Preusser
Brain metastases are a major challenge in modern oncology, as treatment options upon the diagnosis of symptomatic brain metastases are limited. Neo-angiogenesis was identified as a hallmark of brain metastasis development and inhibition using anti-angiogenic therapy might therefore be an experimental promising preventive as well as therapeutic approach. The current review will summarize the current available data on the efficacy of neo-angiogenic therapies in patients with brain metastases.
2018: Memo
https://www.readbyqxmd.com/read/29250206/aggressive-lymphoma-2016-revision-of-the-who-classification
#7
REVIEW
Christine Beham-Schmid
Aggressive lymphomas are a heterogeneous group of malignancies reflecting clinical, biological and pathological diversity. Diffuse large B‑cell lymphoma is the most common histological subtype and therefore will constitute the key aspect in this article. This lymphoma affects patients of all age groups with wide range presentations concerning localization, morphology and molecular mechanisms. The median age at presentation is about 60 years with a slight male preponderance. Up to 50% of patients present with advanced disease...
2017: Memo
https://www.readbyqxmd.com/read/29250205/next-generation-sequencing-clinical-applications-in-solid-tumours
#8
REVIEW
Leonhard Müllauer
Next generation sequencing (NGS) has unravelled the genetic alterations that underlie the pathogenesis of cancer. It is now becoming integrated into routine clinical diagnostics of malignant tumours. NGS supports diagnosis, identifies therapeutic targets, reveals resistance mechanisms and facilitates disease monitoring. It takes a central function in the implementation of cancer therapies adapted to the molecular alterations of tumours.
2017: Memo
https://www.readbyqxmd.com/read/29250204/asco-update-gastrointestinal-tumors
#9
REVIEW
Lukas Weiss, Florian Huemer, Richard Greil
A multitude of new molecular and immunologic insights into gastrointestinal tumors have been presented at the ASCO meeting 2017; however, we have focused our update on practice-changing phase 3 trials and tried to set them into clinical perspective. Furthermore, we will elaborate on updated data on immunotherapeutics in gastroesophageal cancers, since drug approvals may be anticipated before convening for the next meeting in 2018.
2017: Memo
https://www.readbyqxmd.com/read/29250203/asco-2017-highlights-of-gynecological-cancer
#10
REVIEW
Bianca Radl, Brigitte Mlineritsch
At this year's ASCO annual meeting several important studies in the field of gynecological cancer were presented. Here we report a personal selection of the most interesting and clinically relevant data.
2017: Memo
https://www.readbyqxmd.com/read/29250202/asco-2017-highlights-in-breast-cancer
#11
REVIEW
Rupert Bartsch, Elisabeth Bergen
At the 2017 ASCO Annual Meeting, several pertinent studies in the field of breast cancer were presented and some are deemed as being potentially practice changing. BrighTNess was the first phase III study to investigate the addition of carboplatin to standard neoadjuvant chemotherapy in triple-negative breast cancer; while toxicity was increased in the experimental group, a significantly higher pathologic complete remission (pCR) rate was observed as well suggesting that adding carboplatin to neoadjuvant anthracycline, cyclophosphamide and taxane-containing regimens is efficacious in otherwise healthy patients...
2017: Memo
https://www.readbyqxmd.com/read/29250201/asco-update-lung-cancer
#12
REVIEW
Gudrun Absenger, Jasmin Terzic, Angelika Bezan
In the past few years there have been major changes in the treatment landscape in oncology; lung cancer is affected by those changes like almost no other solid tumor. The rise of further second- and third-line tyrosine kinase inhibitors offers sequential therapy for patients with mutated non-small-cell lung cancer. Immunotherapy has found its way into clinical routine and presents us with new challenges in managing side effects, evaluating treatment response and deciding on how long we treat our patients. The treatment algorithm of lung cancer has changed in the last month and further practice-changing trials are coming up, so treating lung cancer patients shows nowadays a more challenging perspective with the possibility of subsequently applied individual therapies...
2017: Memo
https://www.readbyqxmd.com/read/29250200/update-on-squamous-cell-carcinoma-of-the-head-and-neck-asco-annual-meeting-2017
#13
REVIEW
Teresa Magnes, Alexander Egle, Richard Greil, Thomas Melchardt
At the annual ASCO meeting clinically relevant data concerning the management of advanced head and neck cancer that will influence clinical practice in the future were presented. Chemoradiation with high-dose cisplatin remains the mainstay of treatment for patients with locally advanced squamous cell head and neck cancer. Adjuvant therapy with afatinib following chemoradiation failed to show clinical benefit. The combination of bevacizumab with platinum-based chemotherapy improved progression-free survival but did not lead to a significant difference in overall survival compared to chemotherapy alone...
2017: Memo
https://www.readbyqxmd.com/read/29250199/asco-update-on-lymphoma
#14
REVIEW
Michael A Fridrik
s concerning indolent and aggressive lymphoma and multiple myeloma with clinical relevance from the ASCO 2017 meeting are discussed.
2017: Memo
https://www.readbyqxmd.com/read/29250198/novel-concepts-of-antiangiogenic-therapies-in-metastatic-renal-cell-cancer
#15
REVIEW
Renate Pichler, Isabel Heidegger
The era of antiangiogenic drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway has become a mainstay in the treatment of metastatic renal cell carcinoma (mRCC), showing primary responses in 65-70% of patients. Nevertheless, most of those patients progress to angiogenesis inhibitors over time due to different modes of resistance (adaptive and intrinsic). Both in vitro and in vivo analyses provided evidence that PD-L1 upregulation in hypoxia conditions is dependent on hypoxia-inducible factor (HIF)-2alpha and is associated with an overexpression of VEGF...
2017: Memo
https://www.readbyqxmd.com/read/29250197/antiangiogenic-therapies-in-urogenital-malignancies-fiction-or-fact
#16
REVIEW
Friederike Haidl, David Pfister, Axel Heidenreich, Isabel Heidegger
The use of antiangiogenic agents in cancer therapy has become an attractive target in oncological research. However, concerning the uro-oncological field, current guidelines only recommend the use of antiangiogenic agents in metastatic renal cell cancer. Yet in recent years, several approaches for sequential treatment with angiogenesis inhibitors in other urogenital malignancies apart from renal cell cancer are ongoing. Thus, the present review article aims to provide an overview about clinical studies with antiangiogenic agents in prostate-, bladder-, testicular-, as well as penile cancer patients...
2017: Memo
https://www.readbyqxmd.com/read/29250196/antiangiogenic-therapy-in-breast-cancer
#17
REVIEW
Simon Peter Gampenrieder, Theresa Westphal, Richard Greil
Based on a strong rationale for anti-VEGF (vascular endothelial growth factor) treatment in breast cancer and promising preclinical data, great hopes have been placed on the anti-VEGF antibody bevacizumab. Clinical trials, however, reported conflicting results. In metastatic human epidermal growth factor receptor 2(HER2)-negative breast cancer, the addition of bevacizumab to standard chemotherapy improved consistently progression-free survival (PFS), however, without effect on overall survival (OS). In early breast cancer bevacizumab increased the pathologic complete response rate (pCR) after neoadjuvant therapy, but adjuvant trials did not demonstrate an effect on long-term survival...
2017: Memo
https://www.readbyqxmd.com/read/29250195/anti-angiogenic-therapies-for-the-treatment-of-angiosarcoma-a-clinical-update
#18
REVIEW
Robin J Young, Penella J Woll
Angiosarcomas are rare aggressive endothelial tumours, and are associated with a poor prognosis. Due to their vascular nature, there is great interest in their response to anti-angiogenic agents. A number of small prospective studies have reported angiosarcoma response to vascular-targeted agents, including agents that target vascular endothelial growth factor. To date, the response to these agents has been disappointing, and similar to the response observed in other soft tissue sarcoma subtypes. This short review will summarise the recent data in this field...
2017: Memo
https://www.readbyqxmd.com/read/28989544/local-therapies-for-breast-cancer
#19
REVIEW
Ruth Exner
During the San Antonio Breast Cancer Symposium in December 2016, the main topics were systemic treatment of breast cancer and molecular research. But several studies were also presented concerning local therapy: Surgical issues on evaluating resection margins, management of ductal carcinoma in situ (DCIS), surgical challenges after neoadjuvant therapy related to assessment of response or treatment of axillary lymph nodes, and studies about outcome after breast reconstruction and radiation therapy were discussed...
2017: Memo
https://www.readbyqxmd.com/read/28989543/new-diagnostic-tools-for%C3%A2-breast-cancer
#20
REVIEW
Pascal A T Baltzer, Panagiotis Kapetas, Maria Adele Marino, Paola Clauser
Imaging plays a major role in the diagnosis, treatment, and follow-up of breast cancer. Findings that require further assessment will be detected both at screening and curative mammography. Most findings that are further worked up tend to yield benign diagnoses. Consequently, there is an ongoing search for new tools to reduce recalls and unnecessary biopsies while maintaining or improving cancer detection rates. The clinically most promising methods in this respect are described and discussed in this review...
2017: Memo
journal
journal
41897
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"